Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 24;7(4):e0067. doi: 10.1097/HC9.0000000000000067

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

(A) Number of encounters involving supratherapeutic ingestion of acetaminophen-only or acetaminophenopioid products per year. (B) Number of encounters involving supratherapeutic ingestion of codeine/acetaminophen versus hydrocodone/acetaminophen per year. Of note, encounters involving ingestion of oxycodone/acetaminophen, tramadol/acetaminophen, or propoxyphene/acetaminophen were not included in this figure due to very low prevalence. (C) Number of intentional supratherapeutic ingestions of acetaminophen-opioid products per year. (D) Percentage by year of acetaminophen-opioid supratherapeutic ingestion encounters out of the total number of encounters with acetaminophen level >10.